From the magic bullet to theragnostics: Certitudes and hypotheses, trying to optimize the somatostatin model

5Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

The first “theragnostic model”, that of radioiodine, was first applied both in diagnosis and therapy in the 1940s. Since then, many other theragnostic models have been introduced into clinical practice. To bring about the closest pharmacokinetic connection, the radiocompound used for diagnosis and therapy should be the same, although at present this is rarely applicable. Today, a widely applied and effective model is also the “DOTA-Ga-68/Lu-177”, used with success in neuroendocrine tumors (NET). In this paper, we analyze the necessary steps from the in vitro evaluation of a target to the choice of radionuclide and chelate for therapy up to in vivo transition and clinical application of most employed radiocompounds used for theragnostic purposes. Possible future applications and strategies of theragnostic models are also highlighted.

Cite

CITATION STYLE

APA

Di Stasio, G. D., Buonomano, P., Travaini, L. L., Grana, C. M., & Mansi, L. (2021, July 2). From the magic bullet to theragnostics: Certitudes and hypotheses, trying to optimize the somatostatin model. Cancers. MDPI AG. https://doi.org/10.3390/cancers13143474

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free